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ABSTRACT
The CCAAT box is one of the most common elements
in eukaryotic promoters, found in the forward or
reverse orientation. Among the various DNA binding
proteins that interact with this sequence, only NF-Y
(CBF, HAP2/3/4/5) has been shown to absolutely
require all 5 nt. Analysis of a database with 178 bona
fide NF-Y binding sites in 96 unrelated promoters
confirms this need and points to specific additional
flanking nucleotides (C, Pu, Pu on the 5′-side and C/G,
A/G, G,A/C, G on the 3′-side) required for efficient
binding. The frequency of CCAAT boxes appears to be
relatively higher in TATA-less promoters, particularly in
the reverse ATTGG orientation. In TATA-containing
promoters the CCAAT box is preferentially located in
the –80/–100 region (mean position –89) and is not
found nearer to the Start site than –50. In TATA-less
promoters it is usually closer to the +1 signal (at –66 on
average) and is sometimes present in proximity to the
Cap site. The consensus and location of NF-Y binding
sites parallel almost perfectly a previous general
statistical study on CCAAT boxes in 502 unrelated
promoters. This is an indication that NF-Y is the major,
if not the sole, CCAAT box recognizing protein and that
it might serve different roles in TATA-containing and
TATA-less promoters.
CCAAT BOXES AND CCAAT BOX BINDING PROTEINS
Regulation of transcription is a complex set of events controlled
by DNA sequences positioned in proximity to the genes
(promoters) and by elements acting at a distance (enhancers) (1).
Promoters and enhancers that activate polymerase II transcribed
mRNA genes are formed by a combinatorial puzzle of short
sequences recognized by sequence-specific regulators. Some,
such as the TATA, GC and CCAAT boxes, are encountered at
extremely high frequency (2,3). The CCAAT box was one of the
first elements identified (4,5). Later studies clearly established
that such pentanucleotide sequences are present in a wide variety
of vertebrate, yeast and plant promoters and are important for
transcription. Performing a statistical analysis on a compilation of
over 500 unrelated promoters Bucher established that the CCAAT
pentanucleotide is present in ∼30% of them. They are identified by
highly preferred sequences on both the 5′ and 3′ flanking sides and
are most frequently located in the –60/–100 region (3). However,
from this study, it was not possible to identify the protein binding and
activating ‘CCAAT consensus’. Over the last 15 years, with the
parallel discovery of functionally important CCAAT boxes in
different promoters, a plethora of CCAAT-interacting polypeptides
have been detected, mainly by means of EMSA and footprinting
assays. In many cases such activitities were purified and the
corresponding genes cloned.
c/EBP (CCAAT/enhancer binding protein) was identified as
the activator of two functionally important but apparently
unrelated elements in the TK promoter and SV40 enhancer.
Cloning of the genes revealed the presence of B-Zip dimerization
and DNA binding domains (6,7). The binding sites of C/EBP are
composed of palindromic repeats, occasionally containing a
CCAAT pentanucleotide in the intervening sequence (8).
CTF/NF-I (CCAAT transcription factor) also binds as a dimer to
viral and cellular promoters (9), recognizing a TGG(N)6GCCAA
sequence (10). A T after CCAA is sometimes present, but not
strictly necessary, and binding requirements are centred on the two
half palindromes, as confirmed by site selection, saturation
mutagenesis and methylation interference (10,11).
Y Box factors, cloned by screening expression libraries with an
MHC class II Y box oligo (12), were later shown to contain a
nucleic acid interacting protein domain also shared by bacterial
proteins (13). The binding specificity of such proteins is very
large and includes single-stranded DNA, abasic DNA, CT-rich
sequences and class III promoter elements. Moreover, they have
also been involved in the control of translation (13).
CDP (CCAAT displacement protein) was identified as a binding
activity recognizing a large piece of the sea urchin histone H2B and
human γ-globin promoters, both encompassing two CCAAT boxes
(14,15). The gene contains three repeats homologous to the
Drosophila CUT homeodomain (16), each of which has a slightly
different binding specificity, with the CCAAT sequence being
necessary only for CR1 (16,17).
HSP-CBF was cloned by screening expression libraries with an
HSP70 CCAAT oligo (18).
H1TF2A has been purified by affinity chromatography with a
histone H1 CCAAT box. It is a multimeric protein and one of the
genes, H1TF2A, has been cloned and shown to have some
similarity to the Q-rich domain of NF-YA (19,20). The sequence
specifities of the two latter factors are not well defined.
NF-Y (also called CBF, α-CP1 and CP1) was first identified as the
activity binding to the MHC class II conserved Y box (21).
Saturation mutagenensis studies performed in different laboratories
clearly showed an almost absolute requirement for each of the
CCAAT nucleotides (21–24). It was purified independently using
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affinity columns containing the Y box, the α1(I) collagen CCAAT
and the α-globin CCAAT (22,23,25), while conventional
chromatography was used to purify the yeast complex, involved in
activation of cytocrome genes (26). Recently a similar activity was
purified from Neurospora crassa (27). NF-Y is a ubiquitous
heteromeric protein composed of three subunits, NF-YA, NF-YB
and NF-YC, all necessary for DNA binding (28). The mammalian
and yeast genes have been cloned (25,28–37). NF-Y sequences are
available from several other species: the NF-YA gene was cloned
from Schizosaccharomyces pombe, Brassica napus, Schistosoma
mansoni and sea urchin (38–41); NF-YB from Kluyveromyces
lactis, Aspergillus nidulans, Zea mays, lamprey, Xenopus and
chicken (31,42,43). Each of the three subunits displayed highly
conserved domains. The NF-YA homology domain can be sharply
divided into subunit association and DNA contacting subdomains
(34,44–46). NF-YB and NF-YC tight association is a prerequisite
for NF-YA binding and sequence-specific DNA interactions (28).
Both NF-YB and NF-YC conserved domains contain putative
histone fold motifs (47). This motif, common to all core histones,
is composed of three α-helices separated by short loop/strand
regions. Enabling histones to dimerize with companion subunits, this
motif is responsible for formation of the histone octamer. Recent
experiments on yeast HAP3 (34), CBF-A/NF-YB (48) and
CBF-C/NF-YC (49) indicate that this 65 amino acid long motif is
necessary for subunit interactions and DNA binding.
NF-Y CONSENSUS DERIVED FROM NATURAL
PROMOTERS
Because of the apparent multiplicity of CCAAT binding proteins,
a crucial question in understanding how CCAAT sequences
activate transcription is which of the activators shown to
recognize this box is actually operating on a given promoter. To
this end, we and others developed NF-Y reagents, such as
monoclonal and polyclonal antibodies and dominant negative
vectors (46,50), which were employed by many laboratories in
EMSA supershift experiments to unambiguously identify NF-Y
as the DNA–protein complex generated with CCAAT containing
fragments from different promoters.
From this large body of information a database comprising all
promoters shown to contain a bona fide NF-Y binding site was
organized. The following criteria were used. (i) EMSA competition
experiments with the original Ea Y box oligo or with other bona
fide high affinity NF-Y binding sites such as α1(I) collagen,
albumin, α-globin, RSV or MLP (21,22,51). The albumin
promoter was shown to function through a NF-Y binding CCAAT
box (50); a trimeric complex was purified to homogeneity on
α-globin CCAAT affinity columns; subunit composition and
sequence specificities are indistinguishable from NF-Y (23); the
RSV and MLP CCAAT proteins also shared these features
(51,52). (ii) Direct supershift experiments with anti-NF-Y
antibodies. (iii) Promoters of the same gene from different
species, one of which harbours a NF-Y site, were included; in all
cases so far tested [MHC class II, γ-globin, α1 (I) collagen,
albumin, MDR1, topoisomerase IIα] this assumption was in fact
formally proven. (iv) The list of yeast CCAAT-containing
promoters is based upon dependence of the HAP2/3/4/5 complex.
A total of 178 bona fide NF-Y binding sites, 164 in promoters
of higher eukaryotes (mainly human, rodent, chicken and
Xenopus) is presented in Table 1. Information regarding the
position of the CCAAT box with respect to the +1 signal, the
orientation of the CCAAT sequence, the presence in the promoter
of a recognizable TATA box, the role in transcriptional activation,
the proximity of binding sites for other transcription factors and
the tissue distribution of the gene are also presented. In general the
vast majority of these CCAAT boxes have invariably been shown
to significantly contribute to overall promoter strength and,
indeed, sometimes to be strictly required for activity.
Inspection of sequence alignment of all these CCAAT boxes
defines the consensus for NF-Y, as can be seen from Table 2. In
general, although the number of lower eukaryote sequences is
low, the NF-Y and HAP2/3/4/5 consensuses are very similar.
The CCAAT pentanucleotide
All five core nucleotides are almost invariably conserved. The
rare exceptions concern position +2 (an adenine in the globin ρ
enhancer and Apo-A-I and a G in the Ii promoter), position +3 (a T
in CDC25 and Dpa and a G in Factor VIII) and position +5 (C in
MVM P4 and yeast CYC1 and CYT1), while positions +1 and +4
are totally conserved. When measured, such as for Ii, MVM P4
and CYC1, the affinity of the variant CCAAT boxes was lower
than for the intact sequence, highlighting the importance of all 5 nt.
The flanking sequences
At positions –1 and –2 there is a clear preference for purines:
adenines are slightly more abundant at –2 and guanines at –1.
Note that some of the high affinity NF-Y binding sites, such as
α1(I) collagen and RSV, contain a C at position –2. At –3 adenines
are under-represented (<10%), while C residues are more
abundant (>40%). Indeed, a G→C mutation at this position in the
albumin promoter increases both NF-Y binding and promoter
activity. No obvious skewing is seen beyond this position. At the
3′-end guanines are well represented at positions +6/+7 and
predominate at +8, but a clear preference (>50%) is given to C
residues at +6 and A residues at +7. A C→A mutation at +6 and
an A→C at +7 severely affects NF-Y binding to the Y box (21),
while a G→C mutation at +6 of the albumin promoter increases
NF-Y binding and transcriptional activity, as one would expect
from the consensus. Position +10 shows several G residues and
very few C residues. Finally, T residues are seldom found in close
proximity to CCAAT, at positions –1/–2 and from +6 to +9.
Overall, these data fit very well with methylation interference
patterns (see 53). The optimal binding site encompasses 13 nt (3 nt
at the 5′-end and 5 nt at the 3′-end) and thus is slightly over one
turn of the double helix and it is devoid of any recognizable
symmetry axis.
Further confirmation of this analysis comes from sequences that
contain an intact CCAAT pentanucleotide yet bind NF-Y very
inefficiently or not at all. Inspection of such sites (see Table 1)
reinforces the importance of flanking nucleotides, both at the 5′-
and 3′-ends: in β- and ε-globin, in the proximal site of gp91phox,
in hamster topoisomerase IIα site V and in Fcγ receptor 1. The
5′-ends are in accordance with the consensus, except for an
adenine in position –3 of the β-globin site. T residues are present
at different positions between +6 and +8. The IL4 proximal,
human topoisomerase IIα site V and carboxyesterase sites
harbour T residues at –2 and at +7 and +6 respectively. The C
residues at –2, –1 and +7 of the CD14 sites are probably
responsible for its negligible affinity.
Comparison of the NF-Y consensus with the CCAAT Bucher
consensus, statistically derived from random analysis of the most
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frequent sequences in 502 unrelated promoters, show a compel-
ling degree of similarity. The purine preference at the 5′-end (A
residues at –2 and G residues at –1), the high numbers of C
residues at +6 and of A residues at +7, the equal presence of G
residues at these positions, the notable absence of T residues at
–2/–1/+6/+7, are all features that perfectly parallel the numbers
observed for NF-Y binding CCAAT boxes (see Table 2). We note,
however, two differences, a slight over-representation of T
residues at –3 (C residues are more numerous in NF-Y binding
sites) and a relative variance at +4, a position highly conserved for
NF-Y. The latter discrepancy suggests that most, but not all,
CCAAT sequences picked up in the Bucher study are actually
NF-Y binding sites, since a minority of them, ∼15–20%, contain
nucleotides that are at odds with NF-Y binding. In agreement with
this, the frequency of CCAAT-containing promoters as measured
by Bucher (30%) is slightly higher than that we measured on a
larger sample of 1200 promoters, evaluated at 25% (M.Pontoglio
and R.Mantovani, unpublished results). These subtle differences
 Nucleic Acids Research, 1998, Vol. 26, No. 51138
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notwithstanding, one can reasonably conclude that most of the
CCAAT-containing promoters are indeed recognized by NF-Y.
I have also analysed the relative frequency of NF-Y sites with
random DNA totalling twice as much DNA (a 86761 bp contig
sequence from human Xq2.8) as the sum of the promoter
sequences. Seven NF-Y consensus sites were detected (five in the
CCAAT and two in the ATTGG orientation): this is in line with
the theorical frequency of one site every 34096 bp (five sites
expected in both orientations) and indicates that the NF-Y
consensus is not over-represented in random DNA sequences.
Thus NF-Y binding sites are extremely over-represented in promoter
sequences as compared with intergenic DNA. Moreover, it should
be noted that two of the sites pinpointed in this analysis were
within 30 bp of each other, in close proximity to a transcribed
region of the HMG0 gene (T.Vaccari and M.Bianchi, personal
communication), possibly representing true promoter elements.
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Table 1. continued
ARCHITECTURAL FEATURES OF NF-Y BINDING
PROMOTERS
The first observation that can be made as to where the typical
NF-Y binding site is positioned in regulatory regions is that it is
rarely distant from the Start site: only the Ea and Dra Y′ boxes,
the chicken ρ-globin 3′ enhancer and the CYP1A1, FAS and GHR
CCAAT boxes are distant from proximal promoters. Indeed, the
Ea/Dra and FAS genes also have NF-Y sites in their promoters.
The CCAAT sequence can be found both in the direct and in the
inverted orientation and it is present in both TATA-containing
(such as the globins) and in TATA-less (such as MHC class II)
 Nucleic Acids Research, 1998, Vol. 26, No. 51140
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Table 3.
promoters. I therefore analyzed the position of bona fide NF-Y
binding sites with respect to the transcriptional +1 signal, taking
into account two parameters, the orientation of the CCAAT box
and the presence of a TATA box. In higher eukaryotes the CCAAT
box is present in the reverse ATTGG orientation in 60% of cases,
considering both the overall number of sites (99 versus 64) or the
most proximal sites only (73 versus 52) (see Tables 3 and 4).
I next verified how many of the TATA-containing and
TATA-less promoters contain either a CCAAT or an ATTGG
sequence and where, relative to +1, they are positioned. To derive
these data I considered all promoters containing single NF-Y
binding sites and the most proximal sites for those promoters in
which multiple CCAAT are present. Table 4 indicates that 68 out of
119 promoters contain a TATA sequence. This figure of 57%
represents a fair under-representation compared with the frequency
of the TATA box in the overall promoter database as calculated in
the Bucher study (79%), especially since some of the promoters
Table 4.
containing a TATA-like sequence might actually work without it.
In fact, my observations are based upon the presence of a TATA
consensus in the –25/–30 region, but only for very few of these
regions are functional data available, indicating that the TATA
sequence is indeed required. In the case of the Ea promoter, for
example, a TATA-like sequence binding TBP and TFIID is
present at –25, but is functionally irrelevant (54,55).
Comparison of the relative frequencies of CCAAT and ATTGG
boxes in TATA-containing and TATA-less promoters shows clear
skewing: TATA contains roughly equal numbers of CCAAT and
ATTGG (40 and 43 respectively) for the total sites and 34 each if
the analysis is limited to proximal sites (see Table 4). On the other
hand, TATA-less promoters showed a significant difference in
favour of ATTGG (53 versus 20 for total sites and 35 versus 16
considering proximal sites).
I then analyzed the relative distances of the CCAAT/ATTGG
orientations from the Cap site, considering all NF-Y binding sites.
Table 5 shows a peak of ATTGG in the –61/–80 area and many
sites located between –41 and –60, while CCAAT is evenly
distributed in more upstream regions, from –61 to –100. Note the
relatively high number of ATTGG upstream sites beyond –120.
This is largely due to a limited number of promoters with
sequences from multiple species, such as topoisomerase IIα,
containing several NF-Y sites. By limiting the analysis to
proximal sites, the actual number of promoters in which each
NF-Y/TATA arrangement is present can be more precisely
calculated (Table 5): in the CCAAT–TATA combination the
NF-Y sites have a peak between –80 and –100 (mean value 93 ±
25) and 74% of the sites are between –60 and –100; in most of the
ATTGG–TATA-less promoters (62%) the NF-Y binding sites are
located between –41 and –80 (mean value 63 ± 29). A similar
situation is observed with CCAAT–TATA-less, whereas in
ATTGG–TATA most of the NF-Y binding sites are in the
–80/–100 region. Moreover, it is important to note that in the
presence of a TATA box the NF-Y binding CCAAT box is never
closer than –48 in the reverse ATTGG configuration or –62 in the
The list of NF-Y binding sites is as of September 1997.
GENE, the name of the gene is indicated as well as the CCAAT sequence in the promoter. P and D indicate proximal and distal sites respectively. ORG, abbreviated
names of the different species: Hs, man; Rn, rat; Mm, mouse; Bt, bovine; Sp, rabbit; Gg, chicken; Xl, Xenopus laevis; Xt, Xenopus tropicalis; Gc, galago; Ha,
hamster; Cc, quail; Aa, goose; Sm, Schistosoma mansoni; Sc, Saccharomyces cerevisiae; An, Aspergillus nidulans; Nc, Neurospora crassa. OR indicates the
orientation of the NF-Y site: > is forward CCAAT; < is reverse ATTGG. POS is the CCAAT position with respect to the +1 signal, calculated taking into account
the central +3 A. TATA indicates whether the promoter has a consensus TATA sequence in the –20/–30 region. ACT refers to a positive effect on promoter activity,
as tested in functional assays either in vitro or in vivo. TF indicates the presence of a proven binding site for a transcription factor close to the NF-Y binding site. COMP
indicates whether cross-competition data with bona fide NF-Y binding sites are available. AB indicates whether EMSA supershift experiments with anti-NF-Y antibodies
were performed. EXPR refers to the tissue or cell type specificity of the gene activated by NF-Y: Bl, B lymphocytes; Tl, T lymphocytes; Mo, macrophages; Gr,
granulocytes; Ery, erythroid cells; Bo, bone; Sk, skeletal muscle; Li, liver; Sp, spleen; Lu, lung; Ad, adipocytes; My, myoblasts; He, heart; Fi, fibroblast; Sm, smooth
muscle; Ec, embryonal carcinoma; Br, brain; U, ubiquitous; Uind, ubiquitous and inducible; Ts, testis. REF is the reference number. HAP/2/3/4/5 indicates the
dependence of the promoter from intact HAP genes.
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forward CCAAT. It is usually positioned at ∼60 nt from the TBP
binding site, irrespective of orientation. In the absence of a
recognizable TATA box, however, NF-Y sites are much closer to
+1 and in some cases indeed overlap the transcriptional site.
Among the several such examples we find the cell cycle-regulated
genes cdc2, CDC25, cyclin A and cyclin B1, which seem to prefer
the multiple CCAAT–TATA-less configuration.
In conclusion, NF-Y sites show a predominance in proximal
promoter regions; the CCAAT/ATTGG position is far from being
randomly distributed, both in terms of orientation and presence of
a neighbouring TATA box. We take these data as yet another
indication that NF-Y can serve multiple architectural roles in the
functional organization of different classes of promoters and it is
possible that, in the absence of TBP–TATA interactions in the –25
region, NF-Y functions as the pivotal factor in connecting
upstream activators with the general transcription machinery,
thus helping polymerase II to focus on the Start site(s).
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